This page shows what was measured, who it was measured in, and what that does not settle.
What Pomalidomide does in the body
The treatment of adult patients
From the FDA-approved label: Pomalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of pomalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro , in the presence of drug, substrate proteins (including Aiolos and Ikaros) are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · D2UX06XLB5 · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 97 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Occurrence of Treatment Emergent Adverse Events (TEAEs)
✗ The study did not show it
Who was studied
NCT07222761
How many people
915
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Part 1 Safety Lead-In: Incidence of dose limiting toxicities
✗ The study did not show it
Who was studied
NCT05020236
How many people
893
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-Free Survival (PFS)
✗ The study did not show it
Who was studied
NCT05455320
How many people
864
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression Free Survival (PFS)
✗ The study did not show it
Who was studied
NCT06208150
How many people
838
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Progression-free Survival (PFS)
✗ The study did not show it
Who was studied
NCT05519085
How many people
810
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Participants With Treatment Emergent Adverse Events (TEAE)
✗ The study did not show it
Who was studied
NCT01712789
How many people
682
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.2 registered measures of this kind. 3 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.2 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
area under the plasma concentration time curve
time to maximum observed plasma concentration
Meaningful
Things that change how a life goes, not only a number.
progression free survival
time to disease progression
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (36)
a clinical response within the first 6 cycles of treatment
maximum tolerated dose
dose limiting toxicity
confirmed hematologic responses
overall response
phase 1 dose limiting toxicities in cycle 1
best overall response
overall response rate
hematologic response
achieving a primary response at week 32
phase i maximum tolerated dose
phase ii overall response rate
adverse events as a measure of safety and tolerability
adverse events
area under the curve extrapolated to infinity
treatment emergent adverse events
predicted forced vital capacity at week 52
maximum tolerated dose of ace 011
pk renal clearance
pk apparent volume of distribution
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 9.5 hours hours
Read from the label, which states: “Pomalidomide is eliminated with a median plasma half-life of 9.5 hours in healthy subjects and 7.5 hours in patients with MM or KS.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ).
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of POMALYST have not been established in pediatric patients.”
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-30
On older people, the label states: “Multiple Myeloma Of the total number of patients in clinical studies of POMALYST, 44% were aged older than 65 years, while 10% were aged older than 75 years.”
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-30
On people who are pregnant, the label states: “Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in females exposed to POMALYST during pregnancy as well as female partners of male patients who are exposed to POMALYST.”
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of pomalidomide in human milk, the effects of POMALYST on the breastfed child, or the effects of POMALYST on milk production.”
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-30
On people with reduced liver function, the label states: “Pomalidomide is metabolized primarily by the liver.”
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-30
On people with reduced kidney function, the label states: “In patients with severe renal impairment requiring dialysis, the AUC of pomalidomide increased by 38% and the rate of SAE increased by 64% relative to patients with normal renal function; therefore, starting dose adjustment is recommended.”
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S5, S6.
No source is stored against this line.
What is in the pack
Sold as capsule, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Pomalidomide appears in spontaneous reports to regulators. Across the 9 most-reported reaction terms, 11292 reaction mentions were counted. One report can name several reactions.
The recorded terms (9)
pneumonia — 3550 reaction mentions
plasma cell myeloma — 2229 reaction mentions
white blood cell count decreased — 2038 reaction mentions
neuropathy peripheral — 1445 reaction mentions
full blood count decreased — 1049 reaction mentions
laboratory test abnormal — 902 reaction mentions
condition aggravated — 44 reaction mentions
drug interaction — 26 reaction mentions
injection site pain — 9 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
41 products list this as an active ingredient in the United States drug directory. 41 of them contain it and nothing else.
FDA National Drug Code directory · 54893-0038 · read 2026-08-29
They are sold as capsule and powder, taken oral.
FDA National Drug Code directory · 54893-0038 · read 2026-08-29
The regulator's established pharmacologic class for it is thalidomide analog [epc].
FDA National Drug Code directory · 54893-0038 · read 2026-08-29
7 published labels name it as an active ingredient. 7 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-29
Pomalyst is oral at 3 DOSAGE FORMS AND STRENGTHS • Capsules:1 mg, dark blue opaque cap and yellow opaque body, imprinted "POML" on the cap in white ink and "1 mg" on the body in black ink • 2 mg, dark blue opaque cap and orange opaque body…, recorded as fda label in effect 2025-02-26 in the United States.
US prescribing information · 2b25ef01-5c9e-11e1-b86c-0800200c9a66 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Pomalidomide studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Pomalidomide are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
7 documents were read for this substance.
RNAWiki source record
7 of them state the same halfLife, and they agree.
RNAWiki source record
7 of them state the same proteinBinding, and they agree.
RNAWiki source record
7 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
D2UX06XLB5
RxNorm concept
1369718
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S5, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
9 approved applications cover products containing this substance. The earliest was NDA204026, approved 20130208 to BRISTOL.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (13)
Q2
What did Pomalidomide's largest trial (915 people) and its longest (16 years) measure?
915 people in Pomalidomide's largest registered study, 16 years in its longest registered window, measuring area under the plasma concentration-time curve. ClinicalTrials.gov · 2026-09-01
138 phase2, 109 phase1, 46 phase3, 9 na or unstated, 6 na, 2 phase4, 1 early phase1; NCT01562405; 2027-12. Last human test completed 2026, NCT07018401.
Interpretation These counts include studies where Pomalidomide was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
138
phase1
109
phase3
46
na or unstated
9
na
6
phase4
2
2 more recorded rows
early phase1
1
Last recorded human testNCT07018401
2026-06-01
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Pomalidomide shown biomarker?
"This study was terminated for administrative reasons."; 51 of 264 registered studies
Show the evidence
Trial
NCT00537511
terminated; "This study was terminated for administrative reasons."
NCT00717522
terminated; "Study enrollment was terminated due to a corporate strategic decision unrelated to patient safety."
NCT01078974
terminated; "Safety concerns (IgM Flare)"
NCT01198067
terminated; "\<75% participant accrual"
NCT01464034
terminated; "Lack of enrollment"
NCT01537861
terminated; "Unexpected toxicity (2 early deaths)"
14 further recorded trials
NCT01559129
terminated; "Enrollment was stopped early (see limitations and caveats section)."
NCT01728259
terminated; "FDA placed the study on a clinical hold, due to the concerns by the FDA and Health Canada, Celgene decided to permanently close the study."
NCT01807286
terminated; "Sponsor requested termination"
NCT01889420
terminated; "Low accrual"
NCT01946152
terminated; "Per PI at time of CR"
NCT01979276
terminated; "this study was terminated due to losing financial support, and enrollment challenges"
NCT01997840
terminated; "Change in business priorities."
NCT01999335
terminated; "A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ007 was halted during dose-expansion."
NCT02188368
terminated; "Lack of enrollment"
NCT02289222
terminated; "Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the study."
NCT02294357
terminated; "Early termination due to the difficulties to enroll subjects."
NCT02400242
terminated; "Lack of efficacy"
NCT02462525
terminated; "No Go decision for ABBV-838"
NCT02548962
terminated; "After completing Phase 1, the Sponsor elected not to move forward with Phase 2."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Pomalidomide used Pomalidomide 0.5 mg — over how long?
6 recorded entries; human; also "Pomalidomide 0.5 mg", "Pomalidomide 2 MG Oral Capsule [Pomalyst]", "Pomalidomide 4 MG"
Show the evidence
human
NCT01178281
Pomalidomide 0.5 mg
NCT03113942
Pomalidomide 2 MG Oral Capsule [Pomalyst]
NCT03242460
Pomalidomide 4 MG
NCT03424928
Pomalidomide 4 MG Oral Capsule
NCT03424928
Pomalidomide 4 MG Oral Capsule-Pomalyst
NCT06660498
Pomalidomide 2 mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
Pomalidomide's half-life is 9.5 hours — which schedules were studied?
9.5 hours, the half-life Pomalidomide's label states. openfda-label · b1a1c713-d23b-5ede-1ae0-0bbba47221df · 2026-08-30
Show the evidence
half life
9.5 hours hours; Pomalidomide is eliminated with a median plasma half-life of 9.5 hours in healthy subjects and 7.5 hours in patients with MM or KS.
tmax
Effect of Food Co-administration of pomalidomide with a high-fat meal (approximately 50% of the total caloric content) and high-calorie meal (approximately 800 to 1000 calories) (the meal contained approximately 150, 250, and 500 to 600 calories from protein, carbohydrates, and fat, respectively) delays the T max by 2.5 hours, decreased mean plasma C max and AUC in healthy subjects by about 27%…
metabolism
Metabolism Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of a clinical response within the first 6 cycles of treatment, achieving a primary response at week 32 and adverse events did Pomalidomide's trials measure?
a clinical response within the first 6 cycles of treatment, achieving a primary response at week 32 and adverse events lead 40 outcome terms across Pomalidomide's trials. ClinicalTrials.gov · 2026-09-01
confirmed hematologic responses, overall response, phase 1 dose limiting toxicities in cycle 1, best overall response, overall response rate and hematologic response follow.
Show the evidence
a clinical response within the first 6 cycles of treatment
1
maximum tolerated dose
1
dose limiting toxicity
1
confirmed hematologic responses
1
overall response
1
phase 1 dose limiting toxicities in cycle 1
1
14 more recorded rows
best overall response
1
overall response rate
1
hematologic response
1
achieving a primary response at week 32
1
phase i maximum tolerated dose
1
phase ii overall response rate
1
adverse events as a measure of safety and tolerability
1
adverse events
1
area under the plasma concentration time curve
1
time to maximum observed plasma concentration
1
progression free survival
1
area under the curve extrapolated to infinity
1
treatment emergent adverse events
1
predicted forced vital capacity at week 52
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Pomalidomide's 100 ongoing trials reports first?
Maximum Tolerated Dose of ACE-011; Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD); latest 2034-08-23
Show the evidence
Trial
NCT01562405
"Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma"; n 33; "Maximum Tolerated Dose of ACE-011"; 2027-12
NCT02343042
"Selinexor and Backbone Treatments of Multiple Myeloma Patients"; n 300; "Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)"; 2027-04
NCT02406222
"Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)"; n 124; "Progression free survival"; 2025-06
NCT02542657
"Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma"; n 30; "MTD of clarithromycin when given in combination with ixazomib citrate, pomalidomide, and dexamethasone assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)"; 2025-12
NCT02659930
"Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma"; n 62; "safety/tolerability of dose combinations"; 2029-01-01
NCT02718833
"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma"; n 52; "Overall response rate by International Myeloma Working Group criteria."; 2027-12
14 further recorded trials
NCT03030261
"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma"; n 25; "Event-free Survival (EFS) Rate"; 2027-09-26
NCT03539744
"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma."; n 265; "Progression-Free Survival (PFS)"; 2027-11
NCT03715478
"Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex"; n 120; "Recommended Phase 2 Dose (RP2D)"; 2026-12-31
NCT03756896
"Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma"; n 29; "≥ Complete response (CR) rates"; 2026-06-30
NCT04068597
"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies"; n 250; "Incidence of treatment-related adverse events"; 2027-03-31
NCT04094961
"Ixazomib + Pomalidomide + Dexamethasone In MM"; n 52; "Number of participants with dose limiting toxicity"; 2027-01-01
NCT04108195
"A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma"; n 290; "Part 1: Number of Participants With Dose Limiting Toxicity (DLT)"; 2027-04-07
NCT04124497
"A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients"; n 45; "Minimal residual disease (MRD)"; 2027-07-01
NCT04126200
"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)"; n 208; "Number of Participants Randomized Across Sub-studies"; 2027-03-11
NCT04176718
"Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM"; n 44; "Objective response rate of the daratumumab, carfilzomib, pomalidomide, and dexamethasone combination"; 2028-05
NCT04181827
"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma"; n 419; "Progression Free Survival (PFS)"; 2027-03-31
NCT04270175
"Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab"; n 15; "Percentage of Participants With Overall Complete Hematologic Response"; 2028-01
NCT04302324
"A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab"; n 11; "Very Good Partial Response Rate or Better Within 8 Cycles of Induction Therapy"; 2027-12-28
NCT04484623
"Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma"; n 302; "Progression-Free Survival (PFS)"; 2029-06-25
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Pomalidomide could settle lifespan?
NCT02406222 measures Progression free survival, reading out 2025-06.
23 open trials; n 124; "Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)"
Show the evidence
Trial
NCT02406222
"Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)"; n 124; "Progression free survival"; 2025-06
NCT04181827
"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma"; n 419; "Progression Free Survival (PFS)"; 2027-03-31
NCT03030261
"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma"; n 25; "Event-free Survival (EFS) Rate"; 2027-09-26
NCT03539744
"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma."; n 265; "Progression-Free Survival (PFS)"; 2027-11
NCT06158841
"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma"; n 421; "Progression Free Survival (PFS)"; 2027-12
NCT06152575
"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)"; n 492; "Progression free survival per International Myeloma Working Group criteria"; 2027-12-30
14 further recorded trials
NCT05455320
"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment"; n 864; "Progression-Free Survival (PFS)"; 2028-05-25
NCT05083169
"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma"; n 587; "Progression Free Survival (PFS)"; 2028-09-15
NCT06208150
"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide"; n 838; "Progression Free Survival (PFS)"; 2028-12-31
NCT05028348
"A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma"; n 117; "Progression-free survival (PFS)"; 2029-03
NCT04484623
"Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma"; n 302; "Progression-Free Survival (PFS)"; 2029-06-25
NCT06956170
"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma"; n 21; "Progression-Free Survival (PFS)"; 2029-06-25
NCT07760610
"Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response"; n 27; "1-Year Progression-Free Survival Rate"; 2029-07
NCT07138209
"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma"; n 228; "Progression-free Survival (PFS)"; 2029-12
NCT07452198
"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma"; n 358; "Progression Free Survival (PFS)"; 2030-03
NCT06464991
"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)"; n 240; "Progression-Free Survival (PFS) as assessed by Independent Review Committee (IRC)"; 2030-12
NCT07569757
"Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma"; n 260; "Progression-free survival (PFS)"; 2030-12
NCT06413498
"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma"; n 452; "Progression-Free Survival (PFS)"; 2031-07
NCT05572515
"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma"; n 614; "Part 1: Progression-free Survival (PFS)"; 2031-08-31
NCT07772024
"Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma"; n 450; "Progression-free Survival (PFS) assessed by Blinded Independent Central Review (BICR)"; 2031-11
Q10
Which 40 trials of Pomalidomide posted no result?
Posted no result
40 of 40 completed trials
Registrations
NCT00072722, NCT01474330, NCT00482521, NCT01707407, NCT01522547 and NCT01986894, and 34 more
Completion dates
oldest 2005-04; newest 2024-07-30
Show the evidence
Trial
NCT00072722
2005-04
NCT01474330
2011-10-01
NCT00482521
2012-08
NCT01707407
2012-11-01
NCT01522547
2013-12-01
NCT01986894
2013-12-02
14 further recorded trials
NCT01835561
2014-08-21
NCT02168205
2014-09-19
NCT01053949
2015-04
NCT01568294
2015-07-08
NCT01745640
2015-12
NCT02103335
2016-11-30
NCT00949364
2016-12-14
NCT02046915
2017-08-17
NCT03424928
2018-02-06
NCT02206425
2018-03-06
NCT02189343
2018-04-30
NCT01575925
2018-08-07
NCT03242460
2019-05-02
NCT02176213
2019-05-07
Q11
At the median, Pomalidomide's trials enrolled 54 people — anything larger?
Median enrolment
54
Largest enrolment
915
Registered trials counted
262
Q12
What do 11292 spontaneous reports say about Pomalidomide — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Pomalidomide appears in spontaneous reports to regulators. Across the 9 most-reported reaction terms, 11292 reaction mentions were counted: pneumonia 3550; plasma cell myeloma 2229; white blood cell count decreased 2038; neuropathy peripheral 1445. open-targets-adr · CHEMBL43452 · 2026-06-24
Show the evidence
pneumonia
3550
plasma cell myeloma
2229
white blood cell count decreased
2038
neuropathy peripheral
1445
full blood count decreased
1049
laboratory test abnormal
902
3 more recorded rows
condition aggravated
44
drug interaction
26
injection site pain
9
recorded 2026-06-24 · last checked 2026-09-04
Q13
Pomalidomide and CYP3A4, CYP1A2 and P-GP: shared by which compounds?
CYP3A4, CYP1A2 and P-GP appear in Pomalidomide's recorded interaction sentences, 11 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2
pharmacokinetics
Metabolism Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4.
pharmacokinetics
Strong CYP1A2 Inducers: Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied and may reduce pomalidomide exposure.
pharmacokinetics
Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied.
pharmacokinetics
CYP1A2 Inhibitors: Co-administration of fluvoxamine (a strong CYP1A2 inhibitor) with POMALYST increased mean [90% confidence interval] pomalidomide exposure by 125% [98% to 157%] compared to POMALYST alone in healthy subjects.
CYP2C19pharmacokinetics
Minor contributions from CYP2C19 and CYP2D6 were also observed in vitro .
CYP2D6pharmacokinetics
Minor contributions from CYP2C19 and CYP2D6 were also observed in vitro .
CYP3A4
pharmacokinetics
Metabolism Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4.
pharmacokinetics
Drug Interaction Studies Clinical Studies Co-administration of POMALYST with the following drugs did not increase pomalidomide exposure to a clinically significant extent: ketoconazole (a strong CYP3A4 and P-gp inhibitor), carbamazepine (a strong CYP3A4 inducer) and dexamethasone (a weak to moderate CYP3A4 inducer).
pharmacokinetics
Strong CYP3A4 Inducers: Co-administration of carbamazepine to 16 healthy male subjects decreased AUC of pomalidomide by 20% with a 90% confidence interval [13% to 27%] compared to when pomalidomide was administered alone.
pharmacokinetics
Dexamethasone: Co-administration of multiple doses of 4 mg POMALYST with 20 mg to 40 mg dexamethasone (a weak to moderate inducer of CYP3A4) to patients with MM had no effect on the pharmacokinetics of pomalidomide compared to when pomalidomide was administered alone.
pharmacokinetics
Strong CYP3A4 and P-gp Inhibitors: Co-administration of ketoconazole (a strong CYP3A4 and P-gp inhibitor) in 16 healthy male subjects increased AUC of pomalidomide by 19% compared to POMALYST administered alone.
recorded 2026-08-30 · last checked 2026-09-04
Q14
What is recorded about Pomalidomide and mTOR?
"When applied to myeloma, mTOR inhibitors restored sensitivity to pomalidomide, one of the best characterized MGDs, in resistant cell lines and reduced malignant plasma cells in relapsed/refractory patients." — where Pomalidomide and mTOR appear together. Europe PMC · pathway abstract search · 2026-04-01
"When applied to myeloma, mTOR inhibitors restored sensitivity to pomalidomide, one of the best characterized MGDs, in resistant cell lines and reduced malignant plasma cells in relapsed/refractory patients."
PMID 40398155
"In this study, we developed mTOR-targeting PROTACs by conjugating the mTOR agonist MHY-1485 to the Cereblon (CRBN) ligand pomalidomide, demonstrating that even activators can serve as effective warheads for targeted protein degradation."
autophagy
PMID 40373598
"Importantly, pomalidomide enhanced autophagy in a manner dependent on HDAC6."
PMID 40373598
"In conclusion, our findings suggest that pomalidomide resists intracellular Mtb infection through HDAC6-mediated autophagy pathway, positioning it as a promising candidate for TB immunotherapy."
mTORPMID 36436947
"In this study, the mTOR kinase inhibitor MLN0128 was used as the ligand to the protein of interest and conjugated with pomalidomide by diverse intermediate linkage chains."
recorded 2026-04-01 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.